Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Dapagliflozin 10mg + Metformin Hydrochloride I.P. 1000mg Tablets
Therapeutic Category
Diabetic, Antidiabetic
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹289/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Dapoflit M Forte Tablet is a dual-action oral antidiabetic medication combining Dapagliflozin (10mg), a selective SGLT2 inhibitor, with Metformin Hydrochloride (1000mg), a biguanide class agent. This combination helps improve glycemic control in adults with Type 2 Diabetes Mellitus (T2DM) by promoting urinary glucose excretion and reducing hepatic glucose production. The formulation works synergistically to lower blood glucose levels, support weight management, and reduce insulin resistance.
Common side effects include urinary tract infections, genital mycotic infections, nausea, diarrhea, and increased urination. In rare cases, lactic acidosis (with metformin) or ketoacidosis (with dapagliflozin) may occur. Dehydration and hypotension may be observed in volume-depleted individuals.
Dapoflit M Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus, particularly in patients who require dual therapy for adequate blood sugar control. It may also be considered for those at risk of cardiovascular complications associated with diabetes.
Use under medical supervision only. Not recommended in patients with severe renal impairment or active bladder cancer. Monitor renal function and blood glucose regularly. Discontinue temporarily during acute illness, surgery, or dehydration risk to minimize lactic acidosis risk from metformin.
Store in a cool, dry place below 25°C. Protect from moisture and direct sunlight. Keep out of reach of children.
Composition : Dapagliflozin 5mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Fenofibrate I.P. 160mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg + Clopidogrel I.P. 75mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 80mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Aspirin I.P. 75mg Capsules
Composition : Atorvastatin Calcium I.P. 10mg + Clopidogrel I.P. 75mg Tablets
Composition : Sitagliptin Phosphate I.P. 100mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 1000mg Tablets
Composition : Sitagliptin Phosphate I.P. 50mg + Metformin HCL I.P. 500mg Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This antidiabetic combination has strong demand in the diabetes management segment, making it a high-potential product for medical distributors, wholesalers, and pharma franchise partners looking to expand in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes patients requiring dual therapy for better glycemic control. It strengthens their antidiabetic and chronic care portfolio.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Dapagliflozin 10mg + Metformin Hydrochloride Tablet with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong long-term prescription demand, repeat sales, and stable chronic diabetes market growth when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this antidiabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, bulk procurement, pricing details, and distribution support services.